Asparagine-linked (N-linked) protein glycosylation has been observed in all domains of life, including most recently in bacteria and is now widely considered a universal post-translational modification. However, cell-based production of homogeneous glycoproteins for laboratory and preparative purposes remains a significant challenge due in part to the complexity of this process in vivo. To address this issue, an easily available and highly controllable Escherichia coli-based cell-free system for the production of N-linked glycoproteins was developed. The method was created by coupling existing in vitro translation systems with an N-linked glycosylation pathway reconstituted from defined components. The translation/ glycosylation system yielded efficiently glycosylated target proteins at a rate of hundreds of micrograms/milliliters in half a day. This is the first time a prokaryote-based cellfree protein synthesis system has generated N-linked glycoproteins.
Introduction
Cell-free protein-synthesizing systems are emerging as an attractive alternative to conventional expression systems that rely on living cells (for a review, see Katzen et al. 2005) . This is because, over the past decade, cell-free protein synthesis reactions: (i) can be completed in less than a day; (ii) use reagents whose costs are down; (iii) fold complex proteins by routinely forming disulfide bonds; and (iv) can be scaled to 100 L. Two main approaches have been used for in vitro transcription/translation: one is based on cell-free extracts (CFEs), often derived from Escherichia coli, rabbit reticulocytes or wheat germ and the second is based on reconstituted protein synthesis from purified components (Shimizu et al. 2001 ).
Because of their ability to co-activate multiple biochemical networks in a single integrated platform (Jewett et al. 2008) , cell-free systems are increasingly used in many important biotechnology and synthetic biology applications (Ryabova et al. 1997; Noireaux et al. 2003; Yang et al. 2005) .
The ability to accurately and efficiently glycosylate proteins in a cell-free system would have advantages for many areas of basic and applied research, especially given the importance of N-linked glycosylation in protein folding, quality control, sorting, degradation, secretion and activity (Helenius and Aebi 2004) . Unfortunately, the best characterized and most widely used cell-free translation systems based on E. coli are incapable of making glycoproteins because E. coli lack glycosylation machinery. Likewise, rabbit reticulocyte and wheat germ CFE systems cannot perform this post-translational modification because they lack microsomes (Tarui et al. 2000) . This can be overcome by supplementing eukaryotic CFEs with microsomal vesicles (e.g. canine pancreas microsomes; Lingappa et al. 1978; Rothblatt and Meyer 1986) , but the resulting systems do not always faithfully process the target protein due to poor compatibility between some CFEs and microsomal vesicles (Rothblatt and Meyer 1986; Moreno et al. 1991 ). An alternative strategy for creating a cell-free translation system that can execute N-linked glycosylation is to prepare CFEs from specialized cells such as hybridomas (Mikami et al. 2006) , trypanosomes (Moreno et al. 1991) , insect cells (Tarui et al. 2000) or mammalian cells (Shibutani et al. 1996) . However, these systems are technically difficult to prepare and typically result in inefficient glycosylation and low product yields. Moreover, in all the above systems, the glycosylation process is effectively a "black-box" and thus difficult to control.
To address these issues, two novel cell-free translation/glycosylation systems-termed "glycoCFE" and "glycoPURE"-were created here by combining existing in vitro translation systems with a reconstituted N-linked glycosylation pathway. Purified glycosylation components were derived from the protein glycosylation locus ( pgl) present in the genome of the Gram-negative bacterium Campylobacter jejuni (Supplementary data, Figure S1a ). This gene cluster encodes an N-linked glycosylation system that is functionally similar to that of eukaryotes and archaea, involving an oligosaccharyltransferase (OST) that catalyzes the en bloc transfer of preassembled oligosaccharides from lipid carriers onto asparagine residues in a conserved motif [N-X +1 -S/T in eukaryotes and D/E-X −1 -N-X +1 -S/T in bacteria (Kowarik, Young, et al. 2006) , where X −1 and X +1 are any residues except proline] within polypeptides (Supplementary data, Figure S1b ). Several observations suggested that the C. jejuni glycosylation machinery was ideally suited for use in a cell-free translation/glycosylation system. First, E. coli transformed with the entire pgl gene cluster can perform N-linked protein glycosylation (Wacker et al. 2002) , thereby providing a convenient host for producing the necessary components in a pure and active form. Since E. coli lacks native glycosylation machinery, the potential for contamination from background N-or O-linked systems is eliminated. Second, C. jejuni OST, named PglB (CjPglB), is a single-subunit enzyme that is active when solubilized in detergent and, unlike the homologous STT3 subunit of higher organisms, does not require any accessory components for its activity. Third, CjPglB can transfer sugars post-translationally to locally flexible structures in folded proteins , suggesting that protein glycosylation can be achieved without supplementing a functional membrane system (e.g. microsomes).
Results

Preparation of N-linked glycosylation components
To begin, functional reconstitution of bacterial N-linked glycosylation in vitro was attempted. Minimally, this required three components: an OST, a lipid-linked oligosaccharide (LLO) and an acceptor protein carrying the D/E-X −1 -N-X +1 -S/ T motif. For the OST, CjPglB was expressed in the membrane fraction of E. coli cells, solubilized with 1% N-dodecyl-β-D-maltopyranoside (DDM) and purified to near homogeneity by nickel affinity chromatography followed by gel filtration (Supplementary data, Figure S2 ). Separately, E. coli cells carrying the C. jejuni pgl locus were used for producing the oligosaccharide donor. This gene cluster encodes enzymes that carry out the biosynthesis of a GlcGalNAc 5 Bac heptasaccharide (where Bac is bacillosamine) and its transfer from membrane-anchored undecaprenylpyrophosphate (UndPP) to asparagine residues. Here, a modified version of this cluster that carried an inactivated pglB gene (Wacker et al. 2002) was transferred to E. coli SCM6 cells and used to prepare LLOs. SCM6 cells were chosen for several reasons. First, these cells lack the WaaL enzyme that naturally transfers oligosaccharides (e.g. O-antigens, glycans) from the lipid carrier undecaprenyl onto lipid A, which in turn shuttles the oligosaccharides to the outer leaflet of the outer membrane (Feldman et al. 2005) . Thus, in the absence of WaaL, the desired lipid-linked glycans accumulate in the inner membrane. Second, the lipopolysaccharide and enterobacterial common antigen initiating GlcNAc transferase, WecA, is removed. Thus, this strain should only produce LLOs with GlcGalNAc 5 Bac at the reducing end. In support of this notion, previous mass spectrometry analysis of LLOs extracted from an E. coli strain similar to the one used here (i.e. ΔwaaL ΔwecA) revealed that only LLOs containing GlcGalNAc 5 Bac heptasaccharide were detected (Reid et al. 2008) . For the oligosaccharide acceptor, the model glycoprotein AcrA from C. jejuni (Nita-Lazar et al. 2005 ) was purified from the periplasm. AcrA presents two consensus D/E-X 1 -N-X 2 -S/T sites that are glycosylated by CjPglB (Kowarik, Young, et al. 2006) . Alternatively, a glycoengineered single-chain variable fragment (scFv) called scFv13-R4-GT, which carried a C-terminal glycosylation tag (GT) consisting of four consecutive DQNAT motifs separated from one another by consecutive glycine residues (Fisher et al. 2011) , was similarly purified.
Functional reconstitution in vitro of the C. jejuni protein glycosylation pathway To evaluate the reconstituted glycosylation pathway, CjPglB OST was combined with LLOs extracted from E. coli cells Cell-free glycosylation and purified AcrA. This reaction resulted in efficient glycosylation of both AcrA sites as evidenced by the mobility shift of nearly all of the AcrA from the unmodified (g0) to the fully glycosylated (g2) form ( Figure 1A ). This activity was dependent on PglB and LLOs. Doubling the LLO concentration resulted in the appearance of the g0 and g1 forms of AcrA, in addition to g2, suggesting slightly less efficient glycosylation. Importantly, glycosylation activity was lost when lipid extracts from cells lacking the pgl cluster or an inactive CjPglB mutant was used ( Figure 1A) . These results were corroborated by detecting glycosylated AcrA with serum specific for the C. jejuni N-glycan ( Figure 1A ). Nearly identical results were observed when the glycoengineered scFv13-R4-GT protein was used as the oligosaccharide acceptor ( Figure 1A ). It should be noted that g2, g3 and g4 were the predominant glycoforms detected here, with barely detectable levels of g1. To demonstrate that other OSTs could be used in this system, in vitro glycosylation of AcrA was also performed using Campylobacter lari PglB (ClPglB), which is 56% identical to that of C. jejuni (Schwarz et al. 2011 ). This resulted in nearly equal amounts of the g0, g1 and g2 forms of AcrA under the conditions tested ( Figure 1B ). To be useful for translation/glycosylation reactions, the purified glycosylation components must tolerate long-term storage and freeze-thaw cycles. To test this, the components were stored separately at −20°C for 3 months. No changes were made to the storage buffers except that the final concentration of glycerol in the PglB samples was increased to 10%. Each of the components was thawed and refrozen 5-10 times during this period, after which an in vitro reaction with ClPglB was performed. This reaction yielded the glycosylation of AcrA that appeared to be only slightly less efficient than the glycosylation observed with freshly purified components (compare Figure 1B and C).
Cell-free translation of protein targets
To determine whether existing cell-free translation systems could synthesize protein targets of interest, both an E. coli CFE-based protein synthesis system and the PURE ( protein synthesis using recombinant elements) system that uses purified translation components and T7 RNA polymerase (Shimizu et al. 2001) were evaluated. This involved priming the CFE and PURE systems with three different AcrA DNA sequences cloned in a T7 promoter-driven pET vector. Using the CFE system, 150-250 μg/mL of each AcrA variant was produced as a full-length polypeptide in 1 h (Figure 2A ). AcrA carrying its native signal peptide accumulated to the highest level but also experienced the greatest amount of degradation. In contrast, AcrA carrying a PelB signal peptide in place of the native signal and AcrA lacking a signal peptide each accumulated to a slightly lower concentration but experienced no visible degradation. The PURE system similarly produced all three AcrA variants as full-length polypeptides albeit at a slightly lower level ( 100 μg/mL/h of each) than the CFE-based system (Figure 2A ). Both systems were also able to generate appreciable amounts of scFv13-R4-GT (Supplementary data, Figure S3a ). It should be noted that this scFv was previously optimized for expression under nonoxidizing conditions (i.e. in the absence of disulfide bonds) (Martineau et al. 1998 ) and thus did not require special transcription/translation conditions. Cell-free translation and glycosylation of target glycoproteins Encouraged by these results, the glycoCFE and glycoPURE translation/glycosylation systems were constructed by combining the purified glycosylation components (minus the acceptor protein) with one of the cell-free translation systems. The plasmid pET24(AcrA-cyt) that encodes AcrA without an N-terminal signal peptide was chosen to evaluate these systems because it gave rise to significant amounts of target protein in both translation systems with no detectable degradation. When either the CFE or the PURE system were primed with this plasmid along with CjPglB and LLOs, AcrA was produced primarily as the doubly glycosylated g2 glycoform with lesser amounts of g1 and virtually no detectable unmodified AcrA ( Figure 2B ). It was estimated that 100-150 μg of glycosylated AcrA was produced in a 1 mL reaction volume ΔssAcrA was produced by cell-free translation/glycosylation using either the CFE or the PURE systems that were primed with pET24(AcrA-cyt). Controls included the omission of different components (−) or LLOs from SCM6 cells with empty pACYC (+/−).
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after 12 h. Likewise, scFv13-R4-GT was efficiently produced by both the glycoCFE and glycoPURE systems, with 50% of the protein in the fully glycosylated g4 form and 50% in the g3 form (Supplementary data, Figure S3b ). Both systems produced 50-100 μg/mL of glycosylated scFv13-R4-GT in 12 h. Thus, the glycoCFE and glycoPURE systems contain all the components essential for efficiently translating N-linked glycoproteins.
Discussion
A major advantage of the open prokaryote-based translation/ glycosylation systems developed here is that the supply of purified glycosylation components as well as their substrates and cofactors can be provided at precise ratios. Likewise, the concentration of inhibitory substances such as proteases and glycosidases that catalyze the hydrolysis of glycosidic linkages can be reduced or eliminated entirely. Additionally, the in vitro systems permit the introduction of components that may be incompatible with in vivo systems such as certain LLOs that cannot be produced or flipped in vivo. This level of controllability is unavailable in any previous translation/glycosylation system and is significant for several reasons. First, it helps to avoid glycoprotein heterogeneity, which is particularly bothersome in fundamental studies to assess the contribution of specific glycan structures or in pharmaceutical glycoprotein production. Along these lines, the glycoCFE and glycoPURE systems should allow the examination of factors that interact with or stimulate the glycosylation machinery and promote increased acceptor site occupancy. While the glycosylation efficiency observed here with CjPglB exceeded the level typically observed in vivo Kowarik, Young, et al. 2006; Fisher et al. 2011) , it should be pointed out that further study of the reaction conditions should lead to increases in productivity and glycosylation efficiency. Second, it facilitates the integration/co-activation of multiple complex metabolic systems and pathways in vitro including transcription, translation, protein folding and glycosylation. Therefore, the glycoCFE and glycoPURE systems should provide a unique opportunity for studying the interplay of these important mechanisms under conditions where system complexity is reduced and structural barriers are removed. For instance, since the bacterial OST can glycosylate locally flexible structures in folded proteins ) and also structured domains of some proteins (T.J. Mansell and M.P. DeLisa, unpublished observations), these systems should help to decipher the influence of protein structure on glycosylation efficiency. Also, since bacterial and eukaryotic glycosylation mechanisms display significant similarities, these bacterial systems could provide a simplified model framework for understanding the more complex eukaryotic process. Third, it allows for further customization of the system by reconstituting additional or alternative steps (both natural and unnatural) in the glycosylation pathway. For instance, the sequential activities of the glycosyltransferases in the pgl pathway have been reconstituted in vitro (Glover et al. 2005) and could easily be integrated with the translation/glycosylation reactions into a single integrated platform. While glycoengineered E. coli have the potential to provide a wide array of UndPP-linked glycans (Feldman et al. 2005; Yavuz et al. 2011) , the ability to extend beyond bacterial glycans could be achieved by supplementation with specific glycosyltransferases and the requisite activated sugars. This approach could be used for making eukaryotic glycan mimetics (Schwarz et al. 2010 ) and would allow finer control over the diversity of glycoforms that can be used for modifying target proteins in vitro. Since CjPglB has relaxed specificity toward the glycan structure (Feldman et al. 2005) , all of these UndPP-linked glycans are likely to be suitable substrates. Even if CjPglB should prove insufficient, the demonstration here that two different OSTs could be used interchangeably suggests that virtually any single-subunit OST including those from other bacteria, archaea and even some eukaryotes (Nasab et al. 2008 ) could be used in these systems. In support of this notion, the Leishmania major and Pyrococcus furiosus single-subunit OSTs can be functionally expressed in E. coli membranes (M. Aebi, personal communication; Igura and Kohda 2011) . Finally, because one is not limited to natural glycans, the glycoCFE and glycoPURE systems should permit synthesis of hybrid natural/unnatural or even completely artificial glycans. For example, the addition of synthetic sugar-nucleotide donor substrates and/or mutant glycosyltransferases and OSTs having new specificities should enable the construction of a glycosylation system founded on a noncanonical glycan code. For all of these reasons, we anticipate that the glycoCFE and glycoPURE systems will be useful additions to the cell-free translation and glycobiology tookits alike.
Materials and methods
Protein purification
For the purification of CjPglB, E. coli strain C43(DE3) (Lucigen, Middleton, WI) was freshly transformed with plasmid pSN18 ), a modified pBAD expression plasmid encoding C. jejuni pglB with a C-terminal decahistidine affinity tag. Cells were grown in 1.5 L of terrific Broth supplemented with 100 μg/mL of ampicillin at 37°C. When the optical density (A 600 ) of the culture reached 1.0, cells were induced by the addition of 0.02% arabinose (w/v) for 4.5 h at 30°C. All following steps were performed at 4°C unless specified differently. Cells were harvested by centrifugation, resuspended in 25 mM Tris, pH 8.0, and 250 mM NaCl and lysed by three passages through a French press (SLM-Aminco; 10,000 PSI, SLM Instruments, Inc., Urbana, IL). Following the removal of cell debris by centrifugation, the membrane fraction was isolated by ultracentrifugation at 100,000 × g for 1 h. Membranes containing PglB were resuspended in 25 mM pH 8.0, 250 mM NaCl, 10% glycerol (v/v) and 1% DDM (w/v) (DDM, Anatrace, Affymetrix, Inc., Santa Clara, CA) and incubated for 2 h. The insoluble fraction was removed by ultracentrifugation at 100,000 × g for 1 h. All subsequent buffers contained DDM as the detergent. The solubilized membranes were supplemented with 10 mM imidazole, loaded onto a Ni-NTA superflow affinity column (Qiagen, Valencia, CA) and washed with 60 mM imidazole before PglB was eluted Cell-free glycosylation with 200 mM imidazole. The purified protein was then injected onto a Superdex 200 gel filtration column using AKTA-FPLC (GE Healthcare, Waukesha, WI). Eluate fractions were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and stained with Coomassie blue to identify the fractions containing PglB (Supplementary data, Figure S2 ). The protein was desalted with a PD10 desalting column (GE Healthcare) into 20 mM Tris, pH 7.5, 100 mM NaCl, 5% glycerol (w/v) and 0.05% DDM (w/v) and concentrated to 5-10 mg/mL in an Amicon centricon with a molecular mass cutoff of 100 kDa. Expression and purification of the inactive CjPglB mutant was performed identically using except C43(DE3) cells carrying plasmid pSN18.1, which encodes an inactive copy of pglB subcloned from pACYCpgl mut (see below), were used. ClPglB was purified from BL2-Gold(DE3) cells (Stratagene, La Jolla, CA) carrying plasmid pSF2 as described elsewhere . For long-term storage at −20°C, the glycerol content in PglB samples was increased to 10% (w/v).
Purification of AcrA and scFv13-R4-GT was from periplasmic fractions isolated from BL21(DE3) cells carrying plasmid pET24(AcrA-per) (Nita-Lazar et al. 2005) or pET24-ssDsbAscFv13-R4-GT (see below). Periplasmic extracts were prepared as described previously (Schwarz et al. 2011) , supplemented with imidazole to reach a final concentration of 10 mM, sterilefiltered (0.22 μm) and purified by nickel affinity chromatography using Ni-NTA superflow affinity column (Qiagen, Valencia, CA).
Isolation of LLOs
Escherichia coli SCM6 cells transformed with pACYCpgl mut (Wacker et al. 2002) , which codes for the biosynthesis of the C. jejuni LLO and an inactivated C. jejuni pglB gene (W458A and D459A), were grown in 1 L of Luria-Burtani supplemented with 25 μg/mL of chloramphenicol at 37°C. When the A 600 reached 1.0, cells were harvested by centrifugation and the pellet was lyophilized to dryness for 20 h at −80°C and 0.04 mbar. All subsequent steps were performed using glass tubes and glass pipettes. Homogenized pellets were extracted in 25 mL of 10:20:3 CHCl 3 :MeOH:H 2 O followed by centrifugation at 3000 × g for 30 min. The supernatants were evaporated using a rotary evaporator (Büchi, Flawil, Sankt Gallen, Switzerland), after which the resulting pellet was resuspended in 1 mL of 10:20:3 CHCl 3 :MeOH:H 2 O and sonicated until homogenous. The sample was dried under nitrogen gas at 37°C , dissolved in 10 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), pH 7.5, 1 mM MnCl 2 and 0.1% DDM (w/v) and stored at −20°C. An identical procedure was followed to extract lipids from SCM6 cells carrying empty pACYC.
Cell-free translation and glycosylation For in vitro glycosylation of purified acceptor proteins, a 50 μL solution containing 3 μg of purified PglB, 5-10 μL of extracted LLOs and 5 μg of purified AcrA or scFv13-R4-GT in 10 mM HEPES, pH 7.5, 1 mM MnCl 2 and 0.1% DDM (w/v) was incubated for 12 h at 30°C. For in vitro translation of AcrA and scFv13-R4-GT in the absence of glycosylation, a 50 μL reaction was prepared using the S30 T7 High-Yield Expression System (Promega, Fitchburg, WI) or PURExpress (New England Biolabs, Ipswich, MA) according to the manufacturer's instructions. A total of 1 μg of the following plasmids were added to each reaction: pET24b (Novagen, Madison, WI); pET24-AcrA encoding full-length C. jejuni AcrA with a C-terminal hexahistidine tag (Nita-Lazar et al. 2005) ; pET24(AcrA-per) encoding a version of AcrA with an N-terminal PelB signal peptide in place of its native export signal (Nita-Lazar et al. 2005 ); pET24(AcrA-cyt) encoding a version of AcrA without an N-terminal export signal (ΔssAcrA) (Nita-Lazar et al. 2005 ) and pET24-ssDsbA-scFv13-R4-GT encoding the expression-optimized scFv13-R4 intrabody gene (Martineau et al. 1998) with an N-terminal signal peptide from E. coli DsbA for secretion and a C-terminal GT (Fisher et al. 2011) followed by a FLAG and a hexahistidine epitope tag. For in vitro translation/glycosylation reactions, 50 μL of translation reactions was supplemented with 3 μg purified PglB, 5 μL extracted LLOs, 1 μg purified plasmid DNA, 1 mM MnCl 2 and 0.1% DDM (w/v) and incubated for 12 h at 30°C. DDM was chosen for in vitro translation/glycosylation because it was previously observed to be well tolerated in an E. coli-derived CFE system (Klammt et al. 2005) .
Western blot analysis
Expression and glycosylation of AcrA and scFv13-R4-GT was analyzed by immunoblot following SDS-PAGE. Immunodetection was performed with monoclonal anti-His antibody (Qiagen, Valencia, CA), monoclonal anti-FLAG antibody (Abcam, Cambridge, MA), polyclonal anti-AcrA serum (Wacker et al. 2002) and polyclonal anti-glycan serum hR6 (S. Amber and M. Aebi, personal communication). All in vitro translation samples were treated with RNase A (Roche Diagnostics GmbH, Mannheim, Germany) prior to SDS-PAGE to reduce the irregularity of gel electrophoresis due to excess RNA. All experiments were performed at least in triplicate, and representative samples are shown.
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